Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients

doi:10.4254/wjh.v15.i8.964

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5330)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

106

WORD

HTML

2354

Figures (1-2)

426

Tables (1-3)

440

Sum=3359

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

224

Download

820

Sum=1044

Publishing Process of This Article

Item

Count

Browse

166

Download

578

Sum=744

Aug 27, 2023 (publication date) through Jan 17, 2025

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Hepatol. Aug 27, 2023; 15(8): 964-972
Published online Aug 27, 2023. doi: 10.4254/wjh.v15.i8.964

Open in New Tab Full Size Figure Download Figure

Figure 1 Flowchart of study participants. CHB: Chronic hepatitis B; TAF: Tenofovir alafenamide; ETV: Entecavir; TCHO: Total cholesterol; HDL: High density lipoprotein; LDL: Low-density lipoprotein; TG: Triglycerides.

Open in New Tab Full Size Figure Download Figure

Figure 2 Nomogram plot predicted the probability of the elevated total cholesterol level for individual patients receiving tenofovir alafenamide therapy. BMI: Body mass index; CK-MB: Creatine kinase-MB isoenzyme; TCHO: Total cholesterol.

Citation: Lai RM, Lin S, Wang MM, Li N, Zhou JH, Lin XY, Chen TB, Zhu YY, Zheng Q. Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients. World J Hepatol 2023; 15(8): 964-972
URL: https://www.wjgnet.com/1948-5182/full/v15/i8/964.htm
DOI: https://dx.doi.org/10.4254/wjh.v15.i8.964